- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07946770
AI-Assisted Diabetes Education for Children With Type 1 Diabetes
The Effect of Artificial Intelligence-Assisted Education on Quality of Life, Diabetes Management, and Metabolic Control in Children With Type 1 Diabetes
This randomized controlled study evaluates the effects of an artificial intelligence-assisted diabetes education video on quality of life, diabetes self-management skills, and glycemic control in children with type 1 diabetes mellitus. Participants are assigned to an intervention group receiving a 12-minute educational video through a Meta Quest 2 virtual reality headset or a control group receiving routine diabetes education and care. Outcomes are assessed at baseline and at three months using validated questionnaires and routinely recorded HbA1c values.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This single-center, parallel-group randomized controlled study investigates the effects of artificial intelligence-assisted video-based diabetes education on health-related quality of life, diabetes self-management skills, and glycemic control among children and adolescents diagnosed with type 1 diabetes mellitus.
The study is conducted at the Pediatric Endocrinology Outpatient Clinic of Van Training and Research Hospital in Türkiye. A target sample of 60 participants was determined through an a priori power analysis, allowing for potential attrition. Eligible participants are allocated to an intervention group or a control group using a computer-generated random sequence.
Participants in the intervention group receive a 12-minute diabetes education video developed using artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The video content was prepared using established diabetes management guidelines. Artificial intelligence tools were used to develop the educational script, images, digital avatar, and voice narration. The virtual reality headset is used to support attention to the educational material. Disposable protective eye pads and headset cleaning procedures are used between participants to reduce the risk of cross-contamination.
Participants in the control group continue to receive routine diabetes education and clinical care. Outcomes are evaluated at baseline and three months after the intervention. Diabetes-specific quality of life is assessed using the PedsQL 3.0 Diabetes Module, and diabetes self-management skills are assessed using the Life Management Skills Scale for Children With Diabetes. Glycemic control is evaluated using HbA1c values obtained from routinely collected medical records. No additional blood samples or laboratory tests are requested for research purposes.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Nihat Güneş
- Número de telefone: 05373083143
- E-mail: nihatgunes2314@gmail.com
Locais de estudo
-
-
-
Van, Turquia (Türkiye), 65100
- Recrutamento
- Van Training and Research Hospital
-
Contato:
- Nihat güneş
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Children and adolescents within the approved study age range.
- Diagnosis of type 1 diabetes mellitus at least six months before enrollment.
- Regular attendance at scheduled clinical follow-up visits.
- Ability to read and write.
- No communication barriers involving speech, hearing, or vision that would prevent participation.
Exclusion Criteria:
- Presence of a chronic disease other than type 1 diabetes mellitus.
- Unavailability of HbA1c measurements.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: AI-Assisted Diabetes Education
Participants receive a 12-minute diabetes education video developed with artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The educational material addresses essential aspects of type 1 diabetes management and is based on established diabetes guidelines. The headset is used to support participant attention during the educational session. |
Participants in the experimental group receive a 12-minute diabetes education video developed using artificial intelligence tools. The educational content is based on established diabetes management guidelines and covers essential aspects of type 1 diabetes management. The video was prepared using ChatGPT, Gemini, HeyGen, ElevenLabs, and CapCut and is delivered through a Meta Quest 2 virtual reality headset to support attention and engagement. Disposable protective eye pads are used, and the headset is cleaned between participants to reduce the risk of cross-contamination. |
|
Sem intervenção: Routine Diabetes Education and Care
Participants in the control group continue to receive routine diabetes education, follow-up, and clinical care provided by the pediatric endocrinology outpatient clinic. They do not receive the artificial intelligence-assisted educational video. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diabetes-Specific Quality of Life
Prazo: Baseline and Month 3
|
Change in diabetes-specific quality of life from baseline to month 3, assessed using the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module. The 28-item instrument is scored on a 0-100 scale, with higher scores indicating better quality of life. |
Baseline and Month 3
|
|
Diabetes Self-Management Skills
Prazo: Baseline and Month 3
|
Change in diabetes self-management skills from baseline to month 3, assessed using the Life Management Skills Scale for Children With Diabetes. The instrument contains 15 items covering diabetes management knowledge and coping skills. Higher scores indicate better life management skills. |
Baseline and Month 3
|
|
Glycemic Control (HbA1c)
Prazo: Baseline and Month 3
|
Change in glycated hemoglobin (HbA1c) percentage from baseline to month 3. HbA1c values are obtained from medical records following routine physician-ordered clinical assessments. No additional laboratory tests are performed specifically for this study. |
Baseline and Month 3
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- T1DM-AIEDU-2026-01
- GOKAEK/2026-02/68 (Outro identificador: Van Training and Research Hospital Non-Interventional Clinical Research Ethics Committee)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data (IPD) will not be shared with other researchers due to privacy and confidentiality considerations, particularly because the study involves children and adolescents with type 1 diabetes mellitus. Data will be used only for the purposes approved by the ethics committee.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .